- •Serum PCSK9 levels are associated with necrotic core on IVUS-VH of coronary plaque.
- •This association is independent of serum LDL and applies for all patient subgroups.
- •High serum PCSK9 levels are associated with 1-year death and ACS after angiography.
Background and aims
Experimental studies have suggested that proprotein convertase substilisin/kexin type 9 (PCSK9) might directly promote inflammatory processes contributing to atherosclerosis by mechanisms independent of low-density lipoprotein (LDL) cholesterol levels. This study aims to investigate the association between serum PCSK9 levels and the fraction and amount of necrotic core tissue in coronary atherosclerotic plaque, as assessed by intravascular ultrasound virtual histology (IVUS-VH) imaging.
Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery was performed in 581 patients who underwent coronary angiography for acute coronary syndrome (ACS) or stable angina. PCSK9 concentrations were measured in serum samples that were drawn prior to coronary angiography. None of the patients received PCSK9 inhibitors.
After adjustment for established cardiac risk factors, statin use and serum LDL cholesterol, serum PCSK9 levels were linearly associated with the fraction of plaque consisting of necrotic core tissue (β = 1.24% increase per 100 μg/L increase in PCKS9, 95%CI 0.55–1.94, p = 0.001) and with the absolute volume of necrotic core tissue (β = 0.09, 95%CI 0.01–0.18, p = 0.033), but were not significantly associated with plaque burden (p = 0.11), plaque volume (p = 0.22) or the presence of IVUS-VH-derived thin-cap fibroatheroma lesions (p = 1.0).
Serum PCSK9 levels were linearly associated with the fraction and amount of necrotic core tissue in coronary atherosclerosis, independently of serum LDL cholesterol levels and statin use. Therefore, PCSK9 may be an interesting therapeutic target for the treatment of atherosclerotic disease beyond LDL cholesterol regulation.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 928-933
- Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J. Am. Coll. Cardiol. 2013; 62: 1401-1408
- Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.JAMA. 2012; 308: 2497-2506
- Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.Circulation. 2012; 126: 2408-2417
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.Lancet. 2012; 380: 2007-2017
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.Lancet. 2012; 380: 1995-2006
- Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.J. Am. Coll. Cardiol. 2012; 59: 2344-2353
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.Lancet. 2012; 380: 29-36
- Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.New Engl. J. Med. 2012; 367: 1891-1900
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages.Int. J. Mol. Med. 2012; 30: 931-938
- The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.J. Biol. Chem. 2008; 283: 2363-2372
- PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.Mol. Cell Biochem. 2012; 359: 347-358
- Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation.Eurointervention. 2007; 3: 113-120
- In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study.Eur. Heart J. 2014; 35: 639-647
- A prospective natural-history study of coronary atherosclerosis.New Engl. J. Med. 2011; 364: 226-235
- Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study.JACC Cardiovasc. Imaging. 2011; 4: 894-901
- Inflammation in atherosclerosis.Nature. 2002; 420: 868-874
- Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study.EuroIntervention. 2014; 10: 953-960
- In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis.J. Am. Coll. Cardiol. 2005; 46: 2038-2042
- Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting.Eurointervention. 2009; 5: 177-189
- Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.Clin. Chem. 2012; 58: 183-189
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.Nat. Genet. 2003; 34: 154-156
- Commentary PCSK9 variants: a new database.Atherosclerosis. 2009; 203: 32-33
- Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.Nat. Genet. 2005; 37: 161-165
- Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.New Engl. J. Med. 2006; 354: 1264-1272
- Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.J. Lipid Res. 2008; 49: 394-398
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.J. Lipid Res. 2010; 51: 2714-2721
- Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.J. Lipid Res. 2008; 49: 399-409
- Association of proprotein convertase subtilisin/kexin type 9 (pcsk9) with cardiovascular risk in primary prevention.Arterioscler. Thromb. Vasc. Biol. 2015; 35: 2254-2259
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.Atherosclerosis. 2012; 220: 381-386
- Apolipoprotein E induces antiinflammatory phenotype in macrophages.Arterioscler. Thromb. Vasc. Biol. 2011; 31: 1160-1168
- Pathology of the vulnerable plaque.J. Am. Coll. Cardiol. 2006; 47: C13-C18
- Triggering of acute myocardial infarction: beyond the vulnerable plaque.Heart. 2010; 96: 1247-1251
Published online: March 11, 2016
Accepted: March 8, 2016
Received in revised form: March 5, 2016
Received: December 1, 2015
© 2016 Elsevier Ireland Ltd. All rights reserved.